323 results
8-K
EX-99.2
BMY
Bristol-Myers Squibb Co.
25 Apr 24
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
7:47am
(e.g., upper GI & 1L lung) Ex-U.S. demand growth & expanded access Opdualag: U.S. growth driven by strong demand; achieved 25%+ market share3 in 1L … commercial scripts in Q1 Additional momentum driven by continued volume growth and access improvement Continued focus on demand growth and access
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
25 Apr 24
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
7:47am
-performing and inclusive global workforce.
Highlights from the report include:
◦Advancing tailored access programs in low-and middle-income countries … unable to register can access the live conference call by dialing in the U.S. toll-free 1-833-816-1116 or international +1 412-317-0705. Materials related
DEFA14A
BMY
Bristol-Myers Squibb Co.
22 Apr 24
Additional proxy soliciting materials
8:16am
agreement (VPPA) HEALTH EQUITY & ACCESS TO HEALTHCARE BMS has distributed approximately $118.3M in grant funding to support programs and services ESG … memberships for BMS Directors (4) Limit on total board memberships for sitting CEO (2) Proxy access shareholder right Ability to call special meetings
8-K
EX-1.1
5dluo m8g
22 Feb 24
Other Events
4:15pm
424B5
uj7vsu32712rwe
16 Feb 24
Prospectus supplement for primary offering
4:34pm
424B2
xggd0r0jdhg o4
13 Feb 24
Prospectus for primary offering
8:00am
8-K
EX-99.2
87ibnkl1hxsbsdhs
2 Feb 24
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
7:46am
8-K
EX-99.1
nplwm9knw18u7sg9
2 Feb 24
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
7:46am
SC TO-T
EX-99
6ra6tny4j18bi30l yj
25 Jan 24
Third party tender offer statement
8:13am
SC TO-T
EX-99
zgf56vy
25 Jan 24
Third party tender offer statement
8:13am
8-K
EX-99.1
lvec jjw8tu
8 Jan 24
Regulation FD Disclosure
10:29am
DFAN14A
EX-99.1
wqtadjf wxkg
22 Dec 23
Additional proxy materials by non-management
4:21pm
8-K
EX-99.1
b52a5iwoly1f5zcy
22 Dec 23
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
4:15pm
8-K
EX-1.1
tzxbq7max fypiye
13 Nov 23
Other Events
4:19pm
424B5
5v4cg88cvo6t2g
1 Nov 23
Prospectus supplement for primary offering
4:16pm